Furthermore, to better stratify AML patients into different risk groups, a scoring system integrating TP53 mutations with nine other prognostic factors, including age, white blood cell (WBC) count, cytogenetics, NPM1/FLT3-ITD, CEBPA, RUNX1, WT1, DNMT3A and IDH2 mutations, into survival analysis was proposed. The gene discussed is IDH2; the disease is acute myeloid leukemia.